Literature DB >> 29060933

SUMO-specific protease 2-mediated deSUMOylation is required for NDRG2 stabilization in gastric cancer cells.

Xiao-Yan Hu1, Zhe Liu2, Kai-Lin Zhang3, Jing Feng4, Xiao-Fang Liu4, Ling-Yun Wang4, Zi-Wei Wang1.   

Abstract

N-myc downstream regulated gene 2 (NDRG2) is frequently down-regulated in various cancers and functions as a candidate tumor suppressor gene. NDRG2 has been shown to be SUMOylated on the lysine 333 residue, which promoted its ubiquitination and sequentially degradation by the SUMO-targeted ubiquitin E3 ligase RNF4. However, how to regulated NDRG2 deSUMOylation process remains largely unknown. Here, we report that Sentrin/SUMO specific protease (SENP2) was down-regulated in clinic gastric cancer samples and possessed a tumor-suppressive role in gastric cancer. At the molecular level, we found that SENP2 interacts with NDRG2 and mediates the de-SUMOylation process of NDRG2. Overexpression of SENP2 stabilized NDRG2, whereas silencing SENP2 caused rapid NDRG2 SUMOylation and degradation, indicating SENP2 antagonizes NDRG2 ubiquitination and degradation, thereby promoting the stability and function of this protein. Thus, our study reveals that SENP2 acts as a tumor suppressor which is deregulated in gastric cancer and the specific de-SUMOylation activity of SENP2 for NDRG2 is critical for it stabilization as well as gastric cancer cells proliferation.

Entities:  

Keywords:  NDRG2; SENP2; SUMOylation; gastric cancer

Mesh:

Substances:

Year:  2017        PMID: 29060933     DOI: 10.3233/CBM-170651

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  3 in total

1.  SUMO-specific protease 2 (SENP2) functions as a tumor suppressor in osteosarcoma via SOX9 degradation.

Authors:  Hong Pei; Liang Chen; Quan-Ming Liao; Ke-Jun Wang; Shun-Guang Chen; Zheng-Jie Liu; Zhi-Cai Zhang
Journal:  Exp Ther Med       Date:  2018-10-09       Impact factor: 2.447

Review 2.  Cancer-Associated Dysregulation of Sumo Regulators: Proteases and Ligases.

Authors:  Nieves Lara-Ureña; Vahid Jafari; Mario García-Domínguez
Journal:  Int J Mol Sci       Date:  2022-07-20       Impact factor: 6.208

3.  SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway.

Authors:  Xiaohui Tang; Bohao Liu; Chen Zhang; Wenbin Tang; Shitian Liang; Yadan Xiao; Ruoyu Deng; Zhuan Li
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.